Korda
We identify rare disease patients 6-9 years before clinical suspicion
Find the patients who've been waiting.
Clinical Trial Recruitment & Enrollment · RWE · Market Expansion · Post Launch Patient Finding
Sentinel: Truly Scalable Rare Disease Identification
Backed by CZI’s Rare as One Initiative, Sentinel is built for scalability and interoperability:
Our research is able to distinguish between rare diseases, healthy baselines, and phenotypic mimics. We separate true rare disease patients from the common conditions they get mistaken for, collapsing the diagnostic odyssey.
Validated across 10+ rare diseases. Built out of Stanford Medicine and CZI's Rare As One program.
Meet the Team
-
Patcharada (Poppy) Promprasert
Co-Founder & CEO
Stanford Medical School M-TRAM, MS
UC Berkeley, Molecular & Cell Biology, BA
UCSF & Genentech, R&D
-
Yihan (Ayden) Zhao
Co-Founder & CTO
Stanford Medical School BMDS, MS
Tsinghua University CS, BS
Harvard Medical School, BMI
-
Emily Alsentzer
Advisor
Assistant Professor, Stanford University
Stanford University CS, BS
Stanford University BMI, MS
MIT Medical Engineering & Medical Physics, PhD
-
Oscar Alcantar
Advisor
Sr. Director, Head of ClinOps (Maze Tx)
Clinical Program Lead, Biomarin
-
Fabien Beckers
Advisor
Director, X The Moonshot Factory
Founder & CEO, Arterys
-
Ann Mongan
Advisor
Executive Director of Translational Research & Clinical Biomarkers, Bristol Myer Squibb
VP Clinical Biomarkers, Annexon Biosciences
Director Precision Medicine - Oncology, Abbive
Working on a rare disease program?
We can pilot a new disease in Sentinel within weeks.
Clinical Trial Recruitment · Post Launch Patient Finding